Nuclear export inhibitors and kinase inhibitors identified using a MAPK-activated protein kinase 2 redistribution® screen

Assay and Drug Development Technologies

Volumn 2, Issue 1, 2004, Pages 7-20

  Almholt, D L C ^b   Loechel, Frosty ^b   Nielsen, Søren J ^b   Krog Jensen, Christian ^b   Terry, Robert ^b   Bjørn, Sara P ^b   Pedersen, Hans C ^b   Præstegaard, Morten ^b   Møller, Søren ^b   Heide, Morten ^b   Pagliaro, Len ^b   Mason, Anthony J ^b   Butcher, Steven ^b   Dahl, Søren W ^a  

^a BioImage AS   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 TERT BUTYL 2 PHENYL 3,4 DIHYDRO 2H PYRAZOL 3 YL) 3 (2 FLUOROPHENYL)UREA; 1 (5 TERT BUTYL 2,4 TOLYL 2H PYRAZOL 3 YL) 3 [4 (2 MORPHOLIN 4 YL ETHOXY)NAPHTHALEN 1 YL]UREA; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 CHLORO 1 (2,3 DIMETHYLPHENYL) 2,5 DIOXO 2,5 DIHYDRO 1H PYRROL 3 YLAMINO]BENZENESULFONAMIDE; DORAMAPIMOD; LEPTOMYCIN B; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; COLORING AGENT; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; ENZYME INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; OXAZINE DERIVATIVE; PHOSPHOTRANSFERASE; RESAZURIN; XANTHENE DERIVATIVE;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; GENETIC TRANSFECTION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR WEIGHT; MONITOR; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; ACTIVE TRANSPORT; ALGORITHM; BIOSYNTHESIS; CELL LINE; DRUG ANTAGONISM; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; METABOLISM; PLASMID;

ACTIVE TRANSPORT, CELL NUCLEUS; ALGORITHMS; CELL LINE; COLORING AGENTS; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INDICATORS AND REAGENTS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASES; OXAZINES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHOTRANSFERASES; PLASMIDS; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA; XANTHENES;

EID: 2342540450     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/154065804322966270     Document Type: Article

References (37)

1. Chalfie M, Tu Y, Euskirchen G, Ward WW, Prasher DC: Green fluorescent protein as a marker for gene expression. Science 1994;263:802-805.
2. Cubitt AB, Heim R, Adams SR, Boyd AE, Gross LA, Tsien RY: Understanding, improving and using green fluorescent proteins. Trends Biochem Sci 1995;20:448-455.
3. Lippincott-Schwartz J, Snapp E, Kenworthy A: Studying protein dynamics in living cells. Nat Rev Mol Cell Biol 2001;2:444-456.
4. van Roessel P, Brand AH: Imaging into the future: visualizing gene expression and protein interactions with fluorescent proteins. Nat Cell Biol 2002;4:E15-E20.
5. Yoon Y, Pitts K, McNiven M: Studying cytoskeletal dynamics in living cells using green fluorescent protein. Mol Biotechnol 2002;21:241-250.
6. Thastrup O, Tullin S, Poulsen LK, Bjørn SP, inventors; BioImage A/S, assignee: Novel variants of green fluorescent protein, GFP. International application published under the Patent Cooperation Treaty, W097/11094, 1997.
7. Palladino MA, Bahjat FR, Theodorakis EA, Moldawer LL: Anti-TNF-α therapies: the next generation. Nat Rev Drug Discov 2003;2:736-746.
8. Kumar S, Boehm J, Lee JC: p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003;2:717-726.
9. Kyriakis JM, Avruch J: Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001;81:807-869.
10. Engel K, Kotlyarov A, Gaestel M: Leptomycin B-sensitive nuclear export of MAPKAP kinase 2 is regulated by phosphorylation. EMBO J 1998;17:3363-3371.
11. Meng W, Swenson LL, Fitzgibbon MJ, Hayakawa K, Ter Haar E, Behrens AE, Fulghum JR, Lippke JA: Structure of mitogen-activated protein kinase-activated protein (MAPKAP) kinase 2 suggests a bifunctional switch that couples kinase activation with nuclear export. J Biol Chem 2002;277:37401-37405.
12. Neininger A, Thielemann H, Gaestel M: FRET-based detection of different conformations of MK2. EMBO Rep 2001;2:703-708.
13. Ben-Levy R, Leighton IA, Doza YN, Attwood P, Morrice N, Marshall CJ, Cohen P: Identification of novel phosphorylation sites required for activation of MAPKAP kinase-2. EMBO J 1995;14:5920-5930.
14. Engel K, Schultz H, Martin F, Kotlyarov A, Plath K, Hahn M, Heinemann U, Gaestel M: Constitutive activation of mitogen-activated protein kinase-activated protein kinase 2 by mutation of phosphorylation sites and an A-helix motif. J Biol Chem 1995;270:27213-27221.
15. Ben-Levy R, Hooper S, Wilson R, Paterson HF, Marshall CJ: Nuclear export of the stress-activated protein kinase p38 mediated by its substrate MAPKAP kinase-2. Curr Biol 1998;8:1049-1057.
16. Rousseau S, Morrice N, Peggie M, Campbell DG, Gaestel M, Cohen P: Inhibition of SAPK2a/p38 prevents hnRNP A0 phosphorylation by MAPKAP-K2 and its interaction with cytokine mRNAs. EMBO J 2002;21:6505-6514.
17. Bollig F, Winzen R, Gaestel M, Kostka S, Resch K, Holtmann H: Affinity purification of ARE-binding proteins identifies polyA-binding protein 1 as a potential substrate in MK2-induced mRNA stabilization. Biochem Biophys Res Commun 2003;301:665-670.
18. Kotlyarov A, Neininger A, Schubert C, Eckert R, Birchmeier C, Volk HD, Gaestel M: MAPKAP kinase 2 is essential for LPS-induced TNF-α biosynthesis. Nat Cell Biol 1999;1:94-97.
19. Neininger A, Kontoyiannis D, Kotlyarov A, Winzen R, Eckert R, Volk HD, Holtmann H, Kollias G, Gaestel M: MK2 targets AU-rich elements and regulates biosynthesis of tumor necrosis factor and interleukin-6 independently at different post-transcriptional levels. J Biol Chem 2002;277: 3065-3068.
20. Koster M, Lykke-Andersen S, Elnakady YA, Gerth K, Washausen P, Hofle G, Sasse F, Kjems J, Hauser H: Ratjadones inhibit nuclear export by blocking CRM1/exportin 1. Exp Cell Res 2003;286:321-331.
21. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.
22. Hazzalin CA, Cano E, Cuenda A, Barratt MJ, Cohen P, Mahadevan LC: p38/RK is essential for stress-induced nuclear responses: JNK/SAPKs and c-Jun/ATF-2 phosphorylation are insufficient. Curr Biol 1996;6:1028-1031.
23. Hazzalin CA, Le Panse R, Cano E, Mahadevan LC: Anisomycin selectively desensitizes signalling components involved in stress kinase activation and fos and jun induction. Mol Cell Biol 1998;18:1844-1854.
24. Cano E, Doza YN, Ben-Levy R, Cohen P, Mahadevan LC: Identification of anisomycin-activated kinases p45 and p55 in murine cells as MAPKAP kinase-2. Oncogene 1996;12: 805-812.
25. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW, et al.: A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372:739-746.
26. Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, Young PR, Lee JC: SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 1995;364: 229-233.
27. Kudo N, Wolff B, Sekimoto T, Schreiner EP, Yoneda Y, Yanagida M, Horinouchi S, Yoshida M: Leptomycin B inhibition of signal-mediated nuclear export by direct binding to CRM1. Exp Cell Res 1998;242:540-547.
28. Kudo N, Matsumori N, Taoka H, Fujiwara D, Schreiner EP, Wolff B, Yoshida M, Horinouchi S: Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci U S A 1999;96:9112-9117.
29. Neville M, Rosbash M: The NES-Crm1p export pathway is not a major mRNA export route in Saccharomyces cerevisiae. EMBO J 1999;18:3746-3756.
30. Lee JC, Kassis S, Kumar S, Badger A, Adams JL: p38 mitogen-activated protein kinase inhibitors - mechanisms and therapeutic potentials. Pharmacol Ther 1999;82:389-397.
31. Regan J, Breitfelder S, Cirillo P, Gilmore T, Graham AG, Hickey E, Klaus B, Madwed J, Moriak M, Moss N, et al.: Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate. J Med Chem 2002;45:2994-3008.
32. Pargellis C, Tong L, Churchill L, Cirillo PF, Gilmore T, Graham AG, Grob PM, Hickey ER, Moss N, Pav S, et al.: Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol 2002;9:268-272.
33. Regan J, Capolino A, Cirillo PF, Gilmore T, Graham AG, Hickey E, Kroe RR, Madwed J, Moriak M, Nelson R, et al.: Structure-activity relationships of the p38α MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy) naphthalen-1-yl]urea (BIRB 796). J Med Chem 2003;46:4676-4686.
34. Askjaer P, Bachi A, Wilm M, Bischoff FR, Weeks DL, Ogniewski V, Ohno M, Niehrs C, Kjems J, Mattaj IW, et al.: RanGTP-regulated interactions of CRM1 with nucleoporins and a shuttling DEAD-box helicase. Mol Cell Biol 1999;19:6276-6285.
35. Daelemans D, Afonina E, Nilsson J, Werner G, Kjems J, De Clercq E, Pavlakis GN, Vandamme AM: A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. Proc Natl Acad Sci U S A 2002;99:14440-14445.
36. Andersson K, Sundler R: Signalling to translational activation of tumour necrosis factor-α expression in human THP-1 cells. Cytokine 2000;12:1784-1787.
37. Mavunkel BJ, Chakravarty S, Perumattam JJ, Luedtke GR, Liang X, Lim D, Xu YJ, Laney M, Liu DY, Schreiner GF, et al.: Indole-based heterocyclic inhibitors of p38 MAP kinase: designing a conformationally restricted analogue. Bioorg Med Chem Lett 2003;13:3087-3090.